Skip to main content

Steven Treon, MD PhD

Boston, MA
United States

Dana-Farber Cancer Institute

Steve Treon MD, PhD is a Senior Physician and the Director of the Bing Center for Waldenstrom’s Macroglobuliemia (WM) at the Dana Farber Cancer Institute, and a Professor of Medicine at Harvard Medical School. He was the PI for 17 clinical trials which advanced many of the agents currently used to treat WM. By whole-genome sequencing, his laboratory first identified highly recurring MYD88 mutations in WM patients. Translational work in his laboratory showed that BTK was a downstream target of mutated MYD88, enabling a pivotal trial for which he was the PI that led to the first-ever approval of a drug (ibrutinib) and supported the approval and/or development of other BTK-inhibitors for WM. Dr. Treon’s laboratory also identified other critical pro-survival targets related to mutated MYD88 signaling that include IRAK1 and HCK. With the Harvard Medicinal Chemistry Department, he has pursued development of potent and selective inhibitors targeting HCK and IRAK1 for MYD88 mutated lymphomas.

Program Name(s)
Translational Research Program
Dr. Treon